{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:42:52Z","timestamp":1783446172907,"version":"3.55.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the effects of dexamethasone intravitreal implant (DEX) treatment on Diabetic Retinopathy Severity Scale scores and disease progression in patients with diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The 3-year, randomized, Phase 3 MEAD study evaluated DEX 0.35 and 0.7 mg versus sham (treatment at \u22656-month intervals) in patients with diabetic macular edema. This post hoc analysis used data from the sham and pooled DEX arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The proportion of patients with \u22652-step Diabetic Retinopathy Severity Scale score improvement was significantly higher after DEX treatment compared with sham at 24 months only (8.8% vs. 4.2%, OR = 2.1,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016). Among those with \u22652-step Diabetic Retinopathy Severity Scale score improvement, the time to first \u22652-step improvement was shorter with DEX (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; median 400 days with DEX vs. 713 with sham). There were no significant differences between the DEX and sham groups in the proportion of patients who progressed from nonproliferative to proliferative diabetic retinopathy, but among those who progressed, the time to progression was lengthened with DEX (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; median 531.1 days with DEX vs. 191 with sham).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This post hoc analysis of MEAD study data showed that DEX treatment may potentially have a positive impact on diabetic retinopathy by reducing disease severity and slowing progression in patients with diabetic retinopathy with central diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004623","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T21:00:11Z","timestamp":1753477211000},"page":"2252-2262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3648-3772","authenticated-orcid":false,"given":"Kevin J.","family":"Blinder","sequence":"first","affiliation":[{"name":"The Retina Institute, St. Louis, Missouri;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Ferencz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel;"},{"name":"Private Practice, Kfar Saba, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Fang","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Lai","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miller","family":"Ogidigben","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/24741264231156096","article-title":"Evolving treatment patterns in diabetic macular edema between 2015 and 2020","volume":"7","author":"Sodhi","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3928\/23258160-20170329-03","article-title":"Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel","volume":"48","author":"Regillo","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.2147\/OPTH.S286527","article-title":"Sensitive detection of therapeutic efficacy with the ETDRS diabetic retinopathy severity scale","volume":"14","author":"Zhang","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2015-306823","article-title":"Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials","volume":"100","author":"Danis","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.119.4.547","article-title":"How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy","volume":"119","author":"Klein","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ophtha.2017.01.003","article-title":"The clinical importance of changes in diabetic retinopathy severity score","volume":"124","author":"Ip","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-015-0148-2","article-title":"Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study","volume":"15","author":"Augustin","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","article-title":"Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab","volume":"135","author":"Bressler","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R19-20251114","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R20-20251114","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/bmjophth-2022-001007","article-title":"Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension","volume":"7","author":"Goldberg","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"R21-20251114","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2017.06.029","article-title":"Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema: post hoc analyses from VISTA and VIVID","volume":"125","author":"Dhoot","year":"2018","journal-title":"Ophthalmology"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the Protocol W randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R24-20251114","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","article-title":"Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema","volume":"55","author":"Busch","year":"2018","journal-title":"Acta Diabetol"},{"key":"R25-20251114","doi-asserted-by":"crossref","first-page":"e001224","DOI":"10.1136\/bmjophth-2022-001224","article-title":"Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study","volume":"8","author":"Mitchell","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"R26-20251114","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"R27-20251114","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","article-title":"Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"key":"R28-20251114","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00592-018-1117-z","article-title":"Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the 'DR-Pro-DEX Study","volume":"55","author":"Iglicki","year":"2018","journal-title":"Acta Diabetol"},{"key":"R29-20251114","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1038\/s41433-023-02507-x","article-title":"Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema","volume":"37","author":"Kozak","year":"2023","journal-title":"Eye (Lond)"},{"key":"R30-20251114","doi-asserted-by":"crossref","first-page":"100833","DOI":"10.1016\/j.xops.2025.100833","article-title":"Time-in-range analysis of responses after intravitreal dexamethasone therapy in eyes with diabetic macular edema","volume":"5","author":"Kozak","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"R31-20251114","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/1120672119861623","article-title":"Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach","volume":"30","author":"Garc\u00eda Layana","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"R32-20251114","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S206769","article-title":"Dexamethasone implant in the management of diabetic macular edema from clinician's perspective","volume":"13","author":"Urban\u010di\u010d","year":"2019","journal-title":"Clin Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:00:46Z","timestamp":1763132446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004623"}},"subtitle":["Post Hoc Analysis of the MEAD Study"],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004623","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}